title: The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.
abstract: The Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC) is a widely used risk-based calculator used to assess a man's risk of prostate cancer (PCa) before biopsy. This risk calculator was created from data of a patient cohort undergoing a 6-core sextant biopsy, and subsequently validated in men undergoing 12-core systematic biopsy (SBx). The accuracy of the PCPTRC has not been studied in patients undergoing magnetic resonance imaging/ultrasound (MRI/US) fusion-guided biopsy (FBx). We sought to assess the performance of the PCPTRC for straitifying PCa risk in a FBx cohort.
  
  
  
  A review of a prospective cohort undergoing MRI and FBx/SBx was conducted. Data from consecutive FBx/SBx were collected between August 2007 and February 2014, and PCPTRC scores using the PCPTRC2.0R-code were calculated. The risk of positive biopsy and high-grade cancer (Gleason ⩾7) on biopsy was calculated and compared with overall and high-grade cancer detection rates (CDRs). Receiver operating characteristic curves were generated and the areas under the curves (AUCs) were compared using DeLong's test.
  
  
  
  Of 595 men included in the study, PCa was detected in 39% (232) by SBx compared with 48% (287) on combined FBx/SBx biopsy. The PCPTRC AUCs for the CDR were similar (P=0.70) for SBx (0.69) and combined biopsy (0.70). For high-grade disease, AUCs for SBx (0.71) and combined biopsy (0.70) were slightly higher, but were not statistically different (P=0.55).
  
  
  
  In an MRI-screened population of men undergoing FBx, PCPTRC continues to represent a practical method of accurately stratifying PCa risk.
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Maruf
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Fascelli
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: George
authors.affiliation: Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Siddiqui
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kongnyuy
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: DiBianco
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: A
authors.initials: A
authors.lastname: Muthigi
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Valayil
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: A
authors.initials: A
authors.lastname: Sidana
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Frye
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: A
authors.initials: A
authors.lastname: Kilchevsky
authors.affiliation: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Choyke
authors.affiliation: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: B
authors.initials: B
authors.lastname: Turkbey
authors.affiliation: Center for Interventional Oncology, National Cancer Institute & NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Wood
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Urologic Oncology Branch, Bethesda, MD, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Pinto
mesh_terms: D000368:Aged; D055088:Early Detection of Cancer; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration / Q000379:methods*; D006801:Humans; D061705:Image-Guided Biopsy / Q000379:methods*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000000981:diagnostic imaging* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D018570:Risk Assessment